VISUAL AND ANATOMICAL OUTCOMES AFTER VITRECTOMY WITH SUBRETINAL TISSUE PLASMINOGEN ACTIVATOR INJECTION IN PATIENTS WITH SUBMACULAR HEMORRHAGES SECONDARY TO WET AGE-RELATED MACULAR DEGENERATION
Authors:
- 1 November 2025
- journal article
- research article
- Published by Wolters Kluwer Health in RETINAL Cases & Brief Reports
- Vol. 19 (6) , 744-748
Abstract
Purpose: Submacular hemorrhages (SMHs) are most commonly associated with wet age-related macular degeneration and their size and duration are strong prognostic factors for visual outcome. The aim of this audit was to evaluate outcomes of direct injection of submacular tissue plasminogen activator into these lesions during pars plana vitrectomy. Methods: All patients presenting to the Mater Misericordiae Hospital from January 2017 to December 2019 with large submacular hemorrhages secondary to wet age-related macular degeneration who underwent this treatment were included for review. All 10 patients underwent complete pars plana vitrectomy, injection of 0.2 mL (50 μg) of subretinal tissue plasminogen activator, and air tamponade. Preoperative and postoperative evaluations included VA testing, optical coherence tomography, and slit lamp examination. Results: Eight patients (80%) showed improvement of their VA, with four patients achieving a VA of ≤0.4 LogMAR (20/50). Six patients had a total clearing of the macular hemorrhage, with a further two patients having subtotal clearance. One patient subsequently developed a retinal detachment requiring oil tamponade. Conclusion: Submacular hemorrhage secondary to wet age-related macular degeneration is a sight threatening event with a varied prognosis, but in most cases, vitrectomy with subretinal tissue plasminogen activator injection results in improved anatomical and visual outcomes.Keywords
This publication has 9 references indexed in Scilit:
- Management of a Submacular Hemorrhage Secondary to Age-Related Macular Degeneration: A Comparison of Three Treatment ModalitiesJournal of Clinical Medicine, 2020
- Submacular hemorrhage in neovascular age-related macular degeneration: A synthesis of the literatureSurvey of Ophthalmology, 2016
- OPTICAL COHERENCE TOMOGRAPHY FINDINGS AND SURGICAL OUTCOMES OF TISSUE PLASMINOGEN ACTIVATOR–ASSISTED VITRECTOMY FOR SUBMACULAR HEMORRHAGE SECONDARY TO AGE-RELATED MACULAR DEGENERATIONRetina, 2015
- Management of Thick Submacular Hemorrhage With Subretinal Tissue Plasminogen Activator and Pneumatic Displacement for Age-Related Macular DegenerationAmerican Journal of Ophthalmology, 2014
- Long-term outcome of subretinal coapplication of rtPA and bevacizumab followed by repeated intravitreal anti-VEGF injections for neovascular AMD with submacular haemorrhageBritish Journal of Ophthalmology, 2011
- SURGICAL OUTCOMES AFTER MASSIVE SUBRETINAL HEMORRHAGE SECONDARY TO AGE-RELATED MACULAR DEGENERATIONRetina, 2010
- PROSPECTIVE ONE-YEAR STUDY OF RANIBIZUMAB FOR PREDOMINANTLY HEMORRHAGIC CHOROIDAL NEOVASCULAR LESIONS IN AGE-RELATED MACULAR DEGENERATIONRetina, 2010
- Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: Ophthalmic findingsSST report no. 13Ophthalmology, 2004
- Pars plana vitrectomy, subretinal injection of tissue plasminogen activator, and fluid–gas exchange for displacement of thick submacular hemorrhage in age-related macular degenerationAmerican Journal of Ophthalmology, 2001